BioMarin Raises $850M in Senior Notes, Secures $2.8B Debt for Amicus Acquisition
Event summary
- BioMarin plans to issue $850M in senior unsecured notes due 2034.
- Company is syndicating a $2B senior secured term loan B facility, in addition to an existing $800M term loan A facility.
- Total new senior secured credit facilities, including a $600M revolving credit facility, will support the Amicus acquisition.
- Proceeds will fund the acquisition, related fees, and debt obligations.
- Notes are subject to redemption if the acquisition is not completed by December 19, 2026.
The big picture
BioMarin's move to raise significant debt financing underscores its aggressive strategy to expand through acquisition in the rare disease biotechnology sector. The $2.8B in new credit facilities highlights the scale of the Amicus deal and the company's willingness to leverage its balance sheet for growth. This follows broader industry trends of consolidation among biotech firms seeking to strengthen their pipelines and market positions.
What we're watching
- Execution Risk
- Whether BioMarin can successfully close the Amicus acquisition by the December 2026 deadline to avoid redeeming the notes.
- Debt Management
- How BioMarin will manage the increased debt load from the $2.8B in new credit facilities.
- Market Conditions
- The impact of market conditions on the completion of the notes offering and loan syndication.
Related topics